Replies to post #11448 on RespireRx Pharmaceuticals Inc (fka RSPI)

[gfp927z]

Last of my 15 daily free posts --

Cortex also has the only Ampakines to yet be successful in human trials - the low impact compounds. Compound families of other companies are all on the high impact side of the spectrum. Cortex's low impact mechanism may in fact be unique, with no other company able to replicate its ultra safe activity. Cortex's high impacts are as yet an unknown quantity, but these benzamides may have distinct advantages over the compound families of Lilly and others.

If Dr. Stoll were to announce that he's exploring "strategic options" for the company (ie - testing the waters for buyout interest), I wouldn't be surprised to see the stock recover into the $1.25 area, and trend higher from there. If several bidders appear, which is likely, I could see the ultimate selling price in the $2-3 area. That's not great, but would be a lot better than being mired in the sub-buck level, with massive dilution streching out into the horizon.

[striaterminalis]

GFP,

Actually, COR does not have the endocrine patents anymore. These were procured by OLAS pharmaceuticals, who subsequently conducted more experiments in rats to replicate original findings and extend the principle to other hormones. A PR link is attached. Note that the PR describes how ampakiens increase GH and DHEA levels, while reducing levels of CORT. This is significant in two regards. 1) ampakiens induce changes in the levels of GH, DHEA and CORT that are opposite to what occurs during aging. As we age, CORT goes up whle DHEA and GH go down, and this is implicated in many age associated diseases of somatic tissues and CNS, as well as normal aging. Ampakines appear to elevate DHEA and GH, whle reducing CORT. 2) in that there is a link between peripheral GH levels and central BDNF levels, this patent may very well allow them to get in on the neurotrophin angle.

http://biz.yahoo.com/pz/070918/126875.html